IE
BTAI icon

Israel Englander’s BioXcel Therapeutics BTAI Stock Holding History

Israel Englander’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,500
Closed -$266K – 6144
2023
Q2 		$266K Buy
+2,500
New +$832K ﹤0.01% 4964

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Israel Englander's BTAI Position: Q2 2026 in Review

Israel Englander increased its BioXcel Therapeutics (BTAI) stake by 9.2% in Q2 2026, buying an estimated $208K and bringing the position to 2,114,710 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Israel Englander first reported a position in BTAI in Q1 2018 and has held it in 20 quarters since. 46 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Israel Englander held 2,114,710 shares of BioXcel Therapeutics worth $2.98M as of Q2 2026.
  • Israel Englander bought 177,950 BioXcel Therapeutics shares in Q2 2026, an estimated $208K.
  • BioXcel Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3485 holding.
  • Israel Englander first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • 46 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.